The use of thalidomide in the management of bleeding from a gastric cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19304809.
- Also identified by DOI 10.1177/0269216309102526.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Medical management of severe gastrointestinal bleeding can present a therapeutic challenge. We describe a case of bleeding secondary to gastric cancer that failed to settle, despite treatment with tranexamic acid, etamsylate and sucralfate. Thalidomide was prescribed for its antiangiogenic properties. Bleeding settled within 1 week of starting 300 mg of thalidomide nocte. The effect appeared to be dose dependent, with bleeding recurring only when the dose was reduced to 100 mg of thalidomide nocte.
Medical subject headings
- Angiogenesis Inhibitors
- Gastrointestinal Hemorrhage
- Stomach Neoplasms
- Thalidomide